A short review on biosimilars: Future treatment method

Abstract

In living cells, biosimilars are produced and are usually large, complex proteins that can have a variety of uses. Biologics are used in the field of gastroenterology alone for treating inflammatory bowel diseases, tumors, and endocrine disorders. Biosimilar development is an attempt to reduce the cost of the treatment. Currently, seven biosimilars have been approved by the United States Food and Drug Administration (FDA) for use in Crohn‟s disease, ulcerative colitis, and colorectal cancer. There are other biologics involved in treating gastroenterologic diseases for which there are no FDA approved biosimilars. The overview of the article explains the use of biosimilars in the treatment of IBD, Oncology, Diabetics, breast cancer.